Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 35 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Fate Therapeutics Inc | FATE | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.04 | 03:00:03 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.04 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 1 | 35 | - | 1.63 - 8.83 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 03:34:46 | 35 | US$ 3.98 | USD |
Fate Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 400.92M | 99.24M | - | 63.53M | -160.93M | -1.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Fate Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FATE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.79 | 5.02 | 3.74 | 4.12 | 3,187,994 | -0.75 | -15.66% |
| 1 Month | 6.84 | 7.345 | 3.74 | 5.31 | 2,341,113 | -2.80 | -40.94% |
| 3 Months | 6.33 | 8.83 | 3.74 | 6.55 | 2,564,910 | -2.29 | -36.18% |
| 6 Months | 1.63 | 8.83 | 1.63 | 5.17 | 2,461,945 | 2.41 | 147.85% |
| 1 Year | 6.14 | 8.83 | 1.63 | 4.53 | 2,353,554 | -2.10 | -34.20% |
| 3 Years | 87.35 | 97.43 | 1.63 | 18.83 | 1,908,857 | -83.31 | -95.37% |
| 5 Years | 17.40 | 121.16 | 1.63 | 24.79 | 1,516,172 | -13.36 | -76.78% |
Fate Therapeutics Description
| Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. |
